PCN34 COST-EFFECTIVENESS OF ANASTROZOLE OVERTAMOXIFEN IN POSTMENOPAUSAL WOMEN WITH EARLY BREAST CANCER FROM A UK NATIONAL HEALTH SERVICE PERSPECTIVE- THE 5-YEAR COMPLETED TREATMENT ANALYSIS OF THE ATAC TRIAL
Abstract
Authors
R Brown A Benedict R Mansel